B
CTKB icon

Bailard’s Cytek Biosciences CTKB Stock Holding History

Bailard’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$88.2K Hold
19,900
– – ﹤0.01% 759
2026
Q1 		$87K Sell
19,900
-9,400
-32% -$44.4K ﹤0.01% 730
2025
Q4 		$148K Hold
29,300
– – ﹤0.01% 727
2025
Q3 		$102K Buy
+29,300
New +$110K ﹤0.01% 766
2025
Q1 		– Sell
-18,900
Closed -$123K – 760
2024
Q4 		$123K Buy
+18,900
New +$113K ﹤0.01% 713

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bailard's CTKB Position: Q2 2026 in Review

Bailard held its Cytek Biosciences (CTKB) position steady in Q2 2026 at 19,900 shares worth $88.2K. The position accounts for ﹤0.01% of the portfolio, ranked #759.

Bailard first reported a position in CTKB in Q4 2024 and has held it in 5 quarters since. The position peaked at $148K in Q4 2025. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Bailard held 19,900 shares of Cytek Biosciences worth $88.2K as of Q2 2026.
  • Bailard left its Cytek Biosciences share count unchanged in Q2 2026.
  • Cytek Biosciences made up ﹤0.01% of Bailard's portfolio in Q2 2026, its #759 holding.
  • Bailard first reported a position in Cytek Biosciences in Q4 2024 and has held it in 5 quarters since.
  • Bailard's Cytek Biosciences position peaked at $148K in Q4 2025.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Bailard's 13F filing for Q2 2026, filed 30 Jul 2026.